The National Institute for Health and Care Excellence

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable. Fezolinetant (also called Veoza and made by Astellas ...
National Institute for Health and Care Excellence

Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over

This guidance updates and replaces NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088). Next review: This guidance will be ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer TA1138 2 March 2026 2 March 2026 ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. This guidance updates and ...
National Institute for Health and Care Excellence

Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues

We have moved interventional procedures guidance 666 to become HealthTech guidance 535. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...
National Institute for Health and Care Excellence

Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

Isatuximab, plus pomalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults who have had ...
National Institute for Health and Care Excellence

Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment

We have moved health technology evaluation 12 to become HealthTech guidance 696. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...